The FDA-approved drug combination specifically targets low-grade serous ovarian cancer, which primarily affects younger women ...

Luveltamab tazevibulin, a novel ADC, showed encouraging responses in platinum-resistant ovarian cancer, with a 32% ORR and a ...

Scientists at The University of Texas at El Paso have found a promising new target in the fight against high-grade serous carcinoma, an aggressive form of ovarian cancer. Less than 50 percent of women ...

The global burden of ovarian and uterine cancer due to high BMI has increased significantly from 1990 to 2021. Age-standardized rates for uterine cancer rose post-2007, while ovarian cancer showed ...

"We’re in an exciting time for clinical research related to endometrial cancer, with a multitude of novel therapies being developed and in clinical trials right now. We’re making significant ...

Overall, our study provides evidence that CGP significantly improves the identification of molecular targets in HGSOC, supporting its importance in the clinical practice to provide patients with more ...

Ellen Coopersmith rows across the Lake in Central Park. Now that she is retired from her job as a kindergarten teacher, she enjoys spending extra time in New York City when she comes to MSK for her ...

(a) The tumor shows focal glandular architecture along with solid areas (100×, H&E). (b, c) The solid component exhibits prominent lymphocytic infiltrate with tumor heterogeneity (100×, H&E). (d) The ...

(a) Papillary growth pattern with columnar, pseudostratified tumor cells. This morphology can mimic HPV-associated usual-type endocervical adenocarcinoma. (b) Solid growth composed of round to ovoid ...